Genmab — Juni 2023

[Solsen]

https://www.bt.dk/udland/nyt-studie-overrasker-pille-halverer-risikoen-for-at-doe-af-lungekraeft Osimertinib vækker opsigt. Amivantamab går efter det marked (Tagrisso) i kombi med Lazertinib.

[Pensionisten]

Fireside Goldman Sachs - desværre ikke Jan, der deltager (link)

[Pensionisten]

https://ir.genmab.com/genmab-news#content

[E_L]

Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (GMAB – Research Report) today and set a price target of $51.00.

[Klarussen]

Lyder meget rimeligt

[bikube]

Den 22. maj hævede han fra 47 til 51. Det svarer til lidt over 3500 i DK.

[Solsen]

Lidt om Car-T https://endpts.com/new-car-t-data-look-spectacular-but-how-many-patients-will-take-it-and-when-asco23/

[E_L]

longer term results of patients with DLBCL treated with epcoritamab+R-CHOP. The latest results support the preliminary data and this treatment induces high CMR rates with a manageable safety profile https://twitter.com/lymphomahub/status/1666142892270682128

[Bulder]

Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

[Bulder]

Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

De amerikanske lægemiddelmyndigheder FDA har godkendt det bispecifikke antistof epcoritamab til behandling af patienter med relaps eller refraktært (r/r) storce

(haematologisktidsskrift.dk)

[Bulder]

God og grundig artikel, der belyser “styrkeforholdet” epco/glofi/car-t.

[Pensionisten]

Tak for den gode artikel, @Bulder. Den var til at forstå - selv for mig! Og det siger ikke så lidt

[E_L]

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma https://www.onclive.com/view/epcoritamab-plus-rituximab-lenalidomide-produces-responses-in-high-risk-r-r-follicular-lymphoma (this was the oral presentation)

[E_L]

Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506?af=R

[E_L]

so the first article is the new/later cutoff date of January 31, 2023; results very similar

[E_L]

104 efficacy evaluable patients treated with epcoritamab at 48 mg plus R2, the overall response rate (ORR) was 98% (median follow-up, 11.4 months). The complete metabolic response (CMR) was
87%

[E_L]

(versus the the immediate prior therapy they progressed on,
85% and 58% respectively)

[E_L]

easier article maybe - Positive Responses Seen in Follicular Lymphoma When Epcoritamab Is Added to Rituximab and Lenalidomide https://dailynews.ascopubs.org/do/positive-responses-seen-follicular-lymphoma-epcoritamab-added-rituximab-and

[Bulder]

As far as I remember Genmab was planning to file epco for approval in FL this year. But I don’t remember if it was RR or 1L. Do you?

[E_L]

oh good question, i had assumed RR as that is usually the case for a first approval
...